BCPP Prep Series

Registration Options

Webinar Date: 03/30/2020 5:00PM central
Activity Dates: 11/01/2019 - 12/31/2021

Target Audience

This activity has been developed and designed for pharmacists who are preparing to sit for the Board of Pharmacy Specialty (BPS) exam in Psychiatric Pharmacy as they strive to obtain the credentials of Board Certified Psychiatric Pharmacist (BCPP).

Session Summary

This BCPP prep product includes 11 recorded review webinars and one "last-chance" question and answer session with authors/presenters immediately before the Board of Pharmacy Specialties spring and fall testing windows.

Question and Answer Session: The live, last chance Q&A conference call will be scheduled prior to the spring and fall testing windows. The conference call will allow participants the opportunity to ask questions of the Review Course editors immediately prior to BPS spring testing window. Participants can email questions for all topics up to 48 hours prior to the call.

Webinars: The recorded webinar presentations are structured to provide a review of the major topics in the psychiatric pharmacy domains as specified by the BCPP Specialty Council in the current edition of the BPS Candidate's Guide. Webinars feature case-based self-assessment questions with feedback. To obtain optimal benefit, the participant should also purchase the Psychiatric Pharmacotherapy Review Book (check out the bundle cost savings) and have reviewed the chapter for the specified disease state before listening to the recorded presentation. The presenter will be referring the participant back to the chapter for complete details on some items.

View System Requirements to Access All Session Resources

AAPP has invested in supporting the most popular web browsers and leveraging software that our members use daily. Beyond PDF downloads, the rest of the system is built on HTML5, a technology that most up-to-date browsers will support. To access AAPP course materials online, you will need:

A modern web browser with JavaScript and cookies enabled: Chrome is strongly recommended, or the latest version of Firefox or Safari.
A PDF reader: Chrome built-in, Firefox built-in, Acrobat or FoxIt
An adequate device and Internet connection: Processor: Dual-core 2Ghz or higher (Intel i3/i5/i7 or AMD equivalent); Memory: 4 GB; Storage: 5 GB available; Internet speed: 4.0 Mbps (up/down)

AAPP web sites no longer fully support Microsoft Internet Explorer or Windows 8.1 and older. We cannot guarantee that the site will function perfectly on every device and configuration, but using the latest version of the software above will greatly improve your experience.

Faculty Information and Disclosures

Jolene Bostwick, PharmD, BCPS, BCPP

Associate Chair & Clinical Associate Professor, Department of Clinical Pharmacy
University of Michigan College of Pharmacy
Ann Arbor, MI

No Relevant Financial Relationships to Disclose

My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: Generalized anxiety disorder: Benzodiazepines, pregabalin, tiagabine, second generation antipsychotics (olanzapine, risperidone, quetiapine, aripiprazole), trazodone, imipramine, bupropion, escitalopram, vortioxetine, vilazodone, kava, valerian, lavender oil, divalproex/valproate, propranolol

Panic disorder: duloxetine, tricyclic antidepressants (clomipramine, imipramine), mirtazapine, phenelzine, tranylcypromine, benzodiazepines, bupropion, divalproex, gabapentin, levetiracetam, milnacipran, olanzapine, quetiapine, risperidone, aripiprazole, pindolol, tiagabine, vigabatrin, buspirone, trazodone, propranolol

Post-traumatic stress disorder: SSRis (fluoxetine, paroxetine, citalopram, fluvoxamine, escitalopram),

venlafaxine, tricyclic antidepressants including imipramine and amitriptyline, mirtazapine, phenelzine, nefazodone, anticonvulsants (carbamazepine, lamotrigine, topiramate, valproic acid/divalproex sodium, gabapentin, levetiracetam, pregabalin), second generation antipsychotics, adrenergic inhibitors (prazosin, clonidine), second generation antipsychotics (risperidone, olanzapine, aripiprazole, quetiapine), eszopiclone, buspirone, memantine, trazodone, clonidine

Obsessive-compulsive disorder: escitalopram, venlafaxine, mirtazapine, memantine, topiramate, antipsychotics (haloperidol and second generation antipsychotics including aripiprazole, risperidone, quetiapine, olanzapine, ziprasidone), tramadol, phenelzine, tranylcypromine, celecoxib, granisetron, ondansetron, IV ketamine, N-acetylcysteine, pindolol, prebablin, riluzole, clonazepam, clonidine, desipramine, lithium, buspirone, natural products including d-cycloserine

Social anxiety disorder: clonazepam, citalopram, fluoxetine, escitalopram, paroxetine, fluvoxamine, venlafaxine, imipramine, clomipramine, buspirone, gabapentin, pregabalin, propranolol, atenolol, olanzapine, risperidone, aripiprazole, quetiapine, phenelzine, atomoxetine, bupropion, duloxetine, mirtazapine, divalproex, tiagabine, topiramate, levetiracetam, selegiline

Separation anxiety disorder: selective serotonin reuptake inhibitors, venlafaxine, duloxetine, imipramine, desipramine, benzodiazepines

Ryan Carnahan, PharmD, MS, BCPP

Associate Professor
University of Iowa, College of Public Health, Epidemiology
Iowa City, IA

No Relevant Financial Relationships to Disclose

Traci Cole, PharmD, BCPP

Clinical Pharmacy Specialist

Chillicothe VA Medical Center

Chillicothe, OH

No Relevant Financial Relationships to Disclose

Jeremy Daniel, PharmD, BCPP, BCPS

Assistant Professor of Pharmacy Practice

South Dakota State University College of Pharmacy

Sioux Falls, SD

No Relevant Financial Relationships to Disclose

Clayton English, PharmD, BCPS, BCPP, BCGP

Associate Professor

Albany College of Pharmacy and Health Sciences

Colchester, VT

No Relevant Financial Relationships to Disclose

Presentation will include discussion of off-label, experimental, and/or investigational use of drugs or devices: Lithium, triiodothyronne, risperidone, buspirone, ketamine

Lisa Goldstone, PharmD, MS, BCPS, BCPP

Associate Professor of Clinical Pharmacy/Associate Director of Residency Programs

University of Southern California School of Pharmacy

Los Angeles, CA

No Relevant Financial Relationships to Disclose

Megan Maroney, PharmD, BCPP

Clinical Associate Professor

Ernest Mario School of Pharmacy at Rutgers, the State University of New Jersey

Long Branch, NJ

Consultant: Pharmacy Times, Novus Medical Education
Speaker's Bureau: Otsuka Pharmaceuticals, Inc-Excel Speaker's Bureau

Presentation will include discussion of off-label, experimental, and/or investigational use of drugs or devices: Doxepin, melatonin, carbidopa/levodopa, valerian

Sandra Mullen, PharmD, BCPP

Clinical Pharmacy Specialist - Psychiatry

VCU Health Systems

Richmond, VA

My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: Clonidine, guanfacine, valproate, lithium, fluoxetine, citalopram, haloperidol

Kimberly Tallian, PharmD, BCPP, FASHP, FCCP

Advanced Practice Pharmacist - Psychiatry

Scripps Mercy Hospital, San Diego, CA

San Diego, CA

No Relevant Financial Relationships to Disclose

Christopher Thomas, PharmD, BCPP, BCPS

Clinical Pharmacist in Psychiatry

Chillicothe VAMC

Chillicothe, OH

My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: Antipsychotics, mood stabilizers,and antidepressants used for the treatment of Behavioral symptoms associated with Dementia

Gabriela Williams, PharmD, BCPP, BCPS, BCGP

Clinical Pharmacy Specialist, Psychiatry

Eskenazi Health

Indianapolis, IN

My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: TBD-will appropriately identify off-label nature, as necessary

Learning Objectives

Topic
Anxiety and Anxiety-Related Disorders Author: Jolene Bostwick, PharmD, BCPS, BCPP Learning Objectives At the end of this program, the participant should be able to: Identify the most appropriate pharmacologic strategy to manage anxiety given a patient-specific case. Discuss clinical pearls when treating a patient. Describe aspects of patient education necessary for successful management of anxiety disorders.
Biostatistics and Research Design in Psychiatry Author: Ryan Carnahan, PharmD, MS, BCPP Learning Objectives At the end of this program, the participant should be able to: Discuss principles of casual inference as they relate to clinical research. Describe the strengths and weaknesses of common study designs. List common statistical tests for comparing different types of data. Evaluate common sources of bias in clinical research studies.
Bipolar Disorder Author: Jeremy Daniel, PharmD, BCPS, BCPP Learning Objectives At the end of this program, the participant should be able to: Develop patient-specific treatment recommendations given case scenarios. Describe safety and monitoring parameters for mood stabilizers. Discuss treatment recommendations in special populations.
Depression Author: Clayton English, PharmD, BCPS, BCPP, BCGP Learning Objectives At the end of this program, the participant should be able to: Utilize information from the review course outline including treatment guidelines to determine the best course of treatment for a patient with depression. Illustrate common issues encountered while treating depression in clinical practice. Discuss clinical pearls helpful when treating a patient with depression.
Neurocognitive Disorders Author: Christopher Thomas, PharmD, BCPP, BCPS Learning Objectives At the end of this program, the participant should be able to: List diagnostic criteria for neurocognitive disorders. Identify and describe pharmacokinetic and pharmacologic differences between acetylcholinesterase (AChE) inhibitors. Determine the most appropriate pharmacologic (or non-pharmacologic) treatment in the management of behavioral/psychological symptoms of neurocognitive disorders. Describe the gradual dose reduction guidelines for psychotropic agents in skilled nursing facilities. Discuss agents to manage delirium.
Neurodevelopmental, Disruptive, Impulse-Control and Conduct Disorders Author: Sandra Mullen, PharmD, BCPP Learning Objectives At the end of this program, the participant should be able to: Evaluate the treatment for attention-deficit/hyperactivity disorder secondary to adverse effects. Developt a treatment plan for autism spectrum disorder. Assess treatment options for tics disorders. Evaluate impulse control disorders and treatment options.
Neurologic Disorders Author: Kimberly Tallian, PharmD, APH, BCPP, FASHP, FCCP, FCSHP Learning Objectives At the end of this program, the participant should be able to: Describe the signs and symptoms, diagnostic criteria, and pathophysiology for epilepsy, headaches, and Parkinson's Disease. Discuss the efficacy of pharmacologic and non-pharmacologic treatment options (including natural products, if applicable) in the acute and long-term management for epilepsy, headaches, and Parkinson's Disease. Select an evidence-based drug therapy regimen (drug, dose, schedule, and duration of therapy) for stabilizing symptoms and preventing relapse given the clinical presentation of a specific patient with epilepsy, headaches, or Parkinson's Disease.
Personality Disorders and Eating Disorders Author: Traci Cole, PharmD, BCPP Learning Objectives At the end of this program, the participant should be able to: Discuss the efficacy of pharmacologic and non-pharmacologic treatment options for antisocial and borderline personality disorders. Choose the appropriate rating scale for assessment of an eating disorder. Describe guideline-based recommendations for the pharmacologic and non-pharmacologic treatment of eating disorders.
Schizophrenia Spectrum and Other Psychotic Disorders Author: Lisa Goldstone, MS, PharmD, BCPS, BCPP Learning Objectives At the end of this program, the participant should be able to: Describe the diagnostic criteria for schizophrenia spectrum and other psychotic disorders. Design a treatment regimen for schizophrenia or schizoaffective disorder based on guidelines and individual patient factors. Select a pharmacological and/or non-pharmacological approach when adverse effects to medication are present. Discuss considerations when considering treatment for an adolescent with first-episode psychosis.
Sleep-Wake Disorders Author: Megan Maroney, PharmD, BCPP Learning Objectives At the end of this program, the participant should be able to: Describe the clinical presentation of sleep-wake disorders. Discuss rating scales used to evaluate a patient with sleep-wake disorders. Summarize relevant adverse effects and monitoring parameters for medications used to treat sleep-wake disorders. Apply evidence-based guidelines to design an appropriate treatment plan for a patient with a sleep-wake disorder.
Substance-Related Disorders Author: Gabriela Williams, PharmD, BCPS, BCPP Learning Objectives At the end of this program, the participant should be able to: Identify diagnostic criteria as outlined in the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) for substance use disorders. Describe the proposed pathophysiology of substance use disorders. Develop a treatment plan for patients with alcohol use disorder, opioid use disorder, and tobacco use disorder. Identify key principles and potential pharmacotherapy options for the treatment of sedative/hypnotic/anxiolytic (benzodiazepine), stimulant, and cannabis use disorders.

Continuing Education Credit and Disclosures

View AAPP's Privacy Policy

AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.

Questions? Contact AAPP.

View planning committee disclosures

2020-2021 Editorial Board

Megan J. Ehret, PharmD, MS, BCPP
Associate Professor
University of Maryland
Baltimore, MD

No Relevant Financial Relationships to Disclose

Rex S. Lott, PharmD, BCPP
BCPP Program Director
Professor Emeritus of Pharmacy Practice
Idaho State University - College of Pharmacy
Meridian, ID

No Relevant Financial Relationships to Disclose

Carol A. Ott, PharmD, BCPP
Clinical Professor of Pharmacy Practice
Purdue University/Eskenazi Health
Indianapolis, IN

Speaker's Bureau: Project ECHO - Indiana University - Opioid Use Disorders - Expert Panelist,
Tippecanoe County (Indiana) Public Defender's Office - case consultation,
Psychopharmacology Consultation Team - Indiana University - Department of Child Services
Research Grants: Area Health Education Centers - North Central Indiana, Indiana Clinical and Translational Sciences Institute (CTSI)
Non-Financial Interests: Indiana Medicaid Drug Utilization Review (DUR) Board,
Indiana Medicaid Mental Health Quality Advisory Committee (MHQAC), NAMI West Central Indiana

Chris Paxos, PharmD, BCPP, BCPS, BCGP
Pharmacotherapy Specialist
Cleveland Clinic Akron General
Akron, OH

No Relevant Financial Relationships to Disclose

All relevant relationships have been mitigated.

BCPP Prep Series

Back to the BCPP Recertification Products

BCPP Prep Series

Registration Options

Target Audience

Session Summary

Faculty Information and Disclosures

Learning Objectives

Continuing Education Credit and Disclosures